新型快速清除因子VIIa的CT-001增强了产后样本中的静血活性
Derek S Sim1, Cornell R Mallari1, Terry W Hermiston1
1Coagulant Therapeutics, Berkeley, CA.
Blood advances
|December 1, 2023
概括
血静系统在分娩后仍然活跃,尽管消耗了因子,但仍保持了血栓生成. 复合因子VIIa (rFVIIa) 和CT-001都增强了凝血,CT-001在产后出血 (PPH) 治疗中表现出更高的疗效.
科学领域:
- 血液学 血液学 血液学
- 产科 产科 产科 产科 产科
- 药理学 药理学是指药理学的学科.
背景情况:
- 静血系统对于预防分娩期间出血至关重要.
- 有限的数据存在于分娩前和分娩后立即发生的静血变化.
- 复合因子VIIa (rFVIIa) 已被批准用于产后出血 (PPH),CT-001作为下一代疗法.
研究的目的:
- 为了评估孕妇的周周静脉血静状态.
- 为了评估周周血液中rFVIIa和CT-001的ex vivo静血活性.
主要方法:
- 在两个地点对孕妇进行前性观察性研究.
- 在分娩前3天和分娩后45 (±15) 分钟内采集的血液样本.
- 对凝血标志物,血栓生成和粘弹性血液静止试验的分析,包括rFVIIa和CT-001.1.
主要成果:
- 产后显示可溶性纤维素单体和D-二次体增加,组织因子,FVIII,FV和纤维素原减少.
- 血生成试验显示缩短了滞后时间和达到峰值的时间,在分娩后保持了峰值血能力.
- 在分娩后的样本中,rFVIIa和CT-001都增强了凝血活动;CT-001显示出更高的疗效.
结论:
- 尽管消耗了凝血因子,但血栓生成在分娩时保持.
- rFVIIa和CT-001在产后血液样本中有效增强静血活性.
- 与rFVIIa相比,CT-001表现出更高的促凝活性,这表明改善PPH管理的潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Clot Retraction and Fibrinolysis
6.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.2K
Coagulation
6.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.8K
Introduction to Hemostasis
8.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.0K
Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K


